The Multidisciplinary Team Approach: Managing the Newly Diagnosed Patient
Release Date: July 12, 2012
Expiration Date: July 12, 2013
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
Few diseases have undergone more changes in standard of care therapy than multiple myeloma in the last 10 years. With the advent of immunomodulatory drugs such as lenalidomide and thalidomide, the discovery of the proteasome inhibitor bortezomib, and the development of combinations of alkylating agents, immunomodulatory drugs, proteasome inhibitors and steroids, we now have effective therapies that can induce responses in more than 70% of multiple myeloma patients. Myeloma therapy now consists of induction therapy, consolidation therapy in transplant-eligible patients, and most recently, the development of maintenance strategies that can effectively prolong remission durations. The challenge for patients, physicians, nurses, and pharmacists is how to put all of these strategies together to give patients the longest life, with the best quality of life, with a minimum burden of treatment. The other challenge is that the average age of myeloma patients today is over 70 years old. These patients frequently have a number of comorbidities as well as an average of 2 to 3 other drugs they are taking for the management of these comorbidities; this can often present a risk for important drug-drug interactions that need to be taken into account when treating these patients. Thus, a multidisciplinary approach is essential for the appropriate treatment of multiple myeloma patients today. The team has included not only the physicians, but other health care practitioners such as nurses, nurse practitioners, physician assistants, and pharmacists, which are essential for the safe delivery of these very complex chemotherapies, not only in the academic centers, but also in community centers.
This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their management of patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Identify specific considerations for transplant-eligible patients in the selection and administration of primary (induction) as well as maintenance therapy for multiple myeloma, including sequelae and comorbidities.
- Relate the roles of pharmacists and nurses in the initial planning and management of newly diagnosed multiple myeloma patients, including management of side effects and comorbidities.
The Multidisciplinary Team Approach: Managing the Newly Diagnosed Patient– Sergio Giralt, MD
Panel Discussion – Sergio Giralt, MD, R. Donald Harvey, PharmD, BCPS, BCOP, and Beth Faiman, RN, MSN, APRN-BC, AOCN
Instructions for Participation and Credit
This activity is eligible for credit through July 12, 2013. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates may be printed immediately after successfully completing the post-test and activity evaluation.
Sergio A. Giralt, MD
Professor of Medicine
Weill Cornell College of Medicine
Chief, Adult Bone Marrow Transplant Service
Memorial Sloan-Kettering Cancer Center
New York, New York
Dr. Sergio Giralt received his medical degree from Universidad Central de Venezuela and completed his postgraduate internship at the University Hospital of Caracas. He also completed an internal medicine residency at Good Samaritan Hospital in Cincinnati, Ohio, and a postdoctoral fellowship in hematology and oncology at The University of Texas MD Anderson Cancer Center. Dr. Giralt is currently professor of medicine at Weill Cornell College of Medicine and the chief of the Adult Bone Marrow Transplant Service in the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center in New York City.
Board certified in internal medicine, hematology, and medical oncology, Dr. Giralt holds memberships in several professional societies, including the American College of Physicians, American Society of Clinical Oncology, American Society of Hematology, and the North American Society of Blood and Bone Marrow Transplantation, among others. He is a highly sought speaker, lecturer, and presenter who has published hundreds of research articles and abstracts in peer-reviewed literature. Additionally, he is an editorial reviewer for several journals including Blood, Bone Marrow Transplantation, Clinical Cancer Research, Journal of Clinical Oncology, and The Oncologist.
Dr. Giralt’s research focus is on stem cell transplantation for patients with blood disorders and improving treatments for older patients who have acute and chronic leukemia. The development of these less intense and less toxic regimens has changed the standard of care for older patients throughout the world.
R. Donald Harvey III, PharmD, FCCP, BCPS, BCOP
Director, Phase I Program, Winship Cancer Institute
Assistant Professor, Hematology/Medical Oncology
Emory University School of Medicine
Dr. R. Donald Harvey received hisdoctor of pharmacy degree from the University of North Carolina, Chapel Hill. He completed a hematology/oncology specialty residency at UNC Hospitals and School of Pharmacy and a pharmacy practice residency at the University of Kentucky Medical Center and College of Pharmacy. Dr. Harvey is currently director, Phase I Program, Winship Cancer Institute, and assistant professor of hematology/medical oncology at Emory University School of Medicine, Atlanta, Georgia.
Dr. Harvey is a board certified pharmacotherapy specialist and oncology pharmacist. He is a fellow of the American College of Clinical Pharmacy, as well as a member of the American Association for Cancer Research, American Society of Hematology (ASH), and the American Society of Clinical Oncology (ASCO), among others. Dr. Harvey has been published in peer-reviewed journals including Leukemia, Biology of Blood and Marrow Transplantation, Pharmacotherapy, and The Annals of Pharmacotherapy, has written many book chapters and abstracts, and has given many presentations on myeloma and autologous stem cell transplantation.
Beth Faiman, RN, MSN, APRN-BC, AOCN®
Multiple Myeloma Program
Cleveland Clinic Foundation
Beth Faiman received her master of science degree in nursing and certification as an adult nurse practitioner at Kent State University, Ohio. She holds an advanced oncology nurse certification through ANCC and is a pre-doctoral research fellow at the Frances Payne Bolton School of Nursing at Case Western Reserve in Cleveland, Ohio. Ms. Faiman is currently employed as an adult nurse practitioner at the Cleveland Clinic.
A member of several professional associations including the Oncology Nursing Society, Cleveland Chapter Oncology Nursing Society, Ohio Academy of Advanced Practice Nurses, and American Association of Nurse Practitioners, Ms. Faiman is also co-chair of the Nurses Excellence Awards Committee for the Cleveland Clinic, and is current chair of the Advanced Practice Nurse Council for the Cleveland Clinic. In addition, she is an appointed delegate on the Nursing Leadership Board for the International Myeloma Foundation. Ms. Faiman is the editor-in-chief of The Oncology Nurse. She has co-authored several articles relating to the treatment of refractory and relapsing myeloma treatment and has been published in Mayo Clinic Proceedings, Clinical Journal of Oncology Nursing, and has authored several chapters related to diagnosis and management of multiple myeloma. Ms. Faiman is an active presenter and educator on the topics of multiple myeloma, general cancer diagnosis and treatment, as well as management of skeletal and other cancer complications.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-12-314-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 12-314-283
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Sergio Giralt has received honoraria related to speakers’ bureau activities from Celgene Corporation, Genzyme Corporation, Millennium Pharmaceuticals, Inc., Novartis AG, and Onyx Pharmaceuticals. He has received consultant fees from Biokine Therapeutics Ltd. and Celgene.
Dr. R. Donald Harvey and Beth Faiman have disclosed no relevant financial relationships.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, medical director-oncology, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Giralt and Dr. Harvey have indicated that they do intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Beth Faiman has indicated that she does not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Giralt and Beth Faiman have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
Dr. Harvey has indicated that he does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 7.0 or higher, or Firefox 3.0 or higher, a computer running Windows® XP, Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may be Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org.
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Millennium: The Takeda Oncology Company
©2012 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.